> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Fulgent Genetics Signs Lab Lease Starting At $132,071.83 A Month, Rising 3% Annually
- URL: https://www.bullished.co/fulgent-genetics-signs-lab-lease-starting-at-132-071-83-a-month-rising-3-annually-523288fd/
- Published: 2026-11-18T21:36:44.000Z
- Updated: 2026-11-18T21:36:44.000Z
- Description: The Needham space covers approximately 44,644 rentable square feet for diagnostic testing, research and other uses.
- Author: Matteo Parrino
- Tags: SEC Filings, FLGT, Industry: Healthcare

[Fulgent Genetics](https://www.bullished.co/tag/flgt/), which provides laboratory testing and develops cancer treatments, signed a lease Monday starting at [$132,071.83 a month](https://www.sec.gov/Archives/edgar/data/0001674930/000119312526467142/flgt-20261116.htm?ref=bullished.co) in base rent, increasing 3% annually. The company described the commitment in a Wednesday SEC filing for approximately 44,644 rentable square feet in Needham, Massachusetts.

## Rent Beyond The Base Payment

Fulgent leased the property at 63 Kendrick Street from EP 63 Kendrick Realty LLC, the building's landlord. The permitted uses span diagnostic testing, including anatomic pathology, as well as research, offices, warehousing and light manufacturing.

The company must pay a share of operating costs alongside base rent. It is also responsible for repairs, replacements and services inside the space and in areas reserved for its use.

Fulgent is providing a cash security deposit of $792,431, which can decline if specified conditions are met. The landlord's contribution toward improvements is capped at $100 for each rentable square foot.

## Testing And Cancer Drug Development

Fulgent's laboratory business handles genetic and diagnostic tests covering rare diseases, hereditary cancer and reproductive health, alongside pathology services. It also provides testing for pharmaceutical and biotechnology companies.

Consumers can initiate testing through Picture, its telemedicine platform. The laboratory business receives payments from insurers, institutions including hospitals and government bodies, and patients paying directly.

Its therapeutic business uses a nanoencapsulation platform to develop cancer treatments. Drug candidates FID-007 and FID-022 are in clinical trials.

Fulgent operates laboratories in California, Texas, Georgia, Massachusetts and Arizona, as well as Australia. One customer generated $70.8 million of revenue in 2025, representing 22% of the company's total.

## Delivery Protections And Renewal Options

The landlord's [delivery target](https://www.sec.gov/Archives/edgar/data/0001674930/000119312526467142/flgt-20261116.htm?ref=bullished.co) is January 1, 2027\. Specified delays beyond that target entitle Fulgent to base-rent relief; a delay continuing beyond 90 days can give it a right to terminate under the lease's terms.

Fulgent estimates the lease will commence on August 1, 2027, unless final occupancy certification arrives earlier. Base-rent payments begin 180 days after commencement.

The lease expires on the final day of the month falling 126 months after commencement. Fulgent can renew for two successive five-year terms, each at fair market rent.

Learn

- [Item 1.01: entry into a material agreement →](https://www.bullished.co/learn/8-k-items-explained/#item-101-entry-into-a-material-agreement)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Fulgent Genetics, Inc. (FLGT)](https://www.sec.gov/Archives/edgar/data/0001674930/000119312526467142/flgt-20261116.htm?ref=bullished.co) — SEC EDGAR

### More on Fulgent Genetics

- [Fulgent Genetics Improves Loss Outlook As Revenue Reaches $90.4 Million](https://www.bullished.co/fulgent-genetics-improves-loss-outlook-as-revenue-reaches-90-4-million-26f124e8/)
- [Fulgent Genetics Holds $330 Million To $340 Million Revenue Outlook As Billing Fix Drags On](https://www.bullished.co/fulgent-genetics-holds-330-million-to-340-million-revenue-outlook-as-billing-fix-drags-on-e96e2114/)

[All Fulgent Genetics (FLGT) coverage →](https://www.bullished.co/tag/flgt/)